Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: An efficacy and safety, proof-of-principle trial
- PMID: 32852871
- PMCID: PMC8029691
- DOI: 10.1111/jch.13960
Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: An efficacy and safety, proof-of-principle trial
Abstract
Primary aldosteronism (PA) is associated with resistant hypertension and cardiovascular events. There are some limitations of current medical and surgical therapies for PA. To determine the efficacy and safety of catheter-based adrenal artery ablation for treatment of PA patients who refused both surgery and medical therapy, we performed this prospective cohort study. Thirty-six PA patients without apparent aldosteronoma were treated by adrenal artery ablation. Primary outcome was postoperative blood pressure and defined daily dose (DDD) of antihypertensive medications after adrenal ablation. Secondary outcome was biochemical success. We assessed outcomes based on Primary Aldosteronism Surgical Outcome (PASO) criteria. Adrenal CT scan, biochemical evaluation, adrenal artery ablation and adrenal venous sampling (AVS) were underwent. After adrenal ablation, complete clinical success (normotension without antihypertensive medication) was achieved in 9/36 (25.0%) patients and partial clinical success (reduction in blood pressure or less antihypertensive medication) in 13/36 (36.1%) patients. Complete biochemical success (correction of hypokalemia and normalization of aldosterone-to-renin ratio) was achieved in 16/36 (44.4%) patients. Office-based and ambulatory blood pressures were reduced by 17/7 and 11/2 mmHg at 6 months after ablation, respectively. The plasma cortisol level in the ablation group decreased slightly, but no patient developed hypoadrenocorticism. Catheter-based adrenal ablation appears to produce substantial and sustained blood pressure reduction and biochemical improvement, with only minor adverse events in PA patients without apparent aldosteronoma. This therapy could be an important supplement for current PA treatments.
Keywords: adrenal artery ablation; antihypertensive therapy; efficacy and safety; primary aldosteronism.
©2020 Wiley Periodicals LLC.
Conflict of interest statement
None.
Figures


Similar articles
-
Rationality and implication of catheter-based adrenal ablation for bilateral primary aldosteronism.Hypertens Res. 2024 Oct;47(10):2884-2894. doi: 10.1038/s41440-024-01815-3. Hypertens Res. 2024. PMID: 39117945
-
Superselective adrenal arterial embolization for primary aldosteronism without lateralized aldosterone secretion: an efficacy and safety, proof-of-principle study.Hypertens Res. 2023 May;46(5):1297-1310. doi: 10.1038/s41440-023-01236-8. Epub 2023 Mar 3. Hypertens Res. 2023. PMID: 36869143
-
Endoscopic, ultrasound-guided, radiofrequency ablation of aldosterone-producing adenomas (FABULAS): a UK, multicentre, prospective, proof-of-concept trial.Lancet. 2025 Feb 22;405(10479):637-647. doi: 10.1016/S0140-6736(24)02755-7. Epub 2025 Feb 7. Lancet. 2025. PMID: 39929216
-
Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism.Orphanet J Rare Dis. 2010 May 19;5:9. doi: 10.1186/1750-1172-5-9. Orphanet J Rare Dis. 2010. PMID: 20482833 Free PMC article. Review.
-
Selection of patients for surgery for primary aldosteronism.Clin Exp Pharmacol Physiol. 2008 Apr;35(4):522-5. doi: 10.1111/j.1440-1681.2008.04909.x. Clin Exp Pharmacol Physiol. 2008. PMID: 18307754 Review.
Cited by
-
Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks.Endocr Rev. 2024 Jan 4;45(1):125-170. doi: 10.1210/endrev/bnad026. Endocr Rev. 2024. PMID: 37556722 Free PMC article.
-
Safety and efficacy of bilateral superselective adrenal arterial embolization for treatment of idiopathic hyperaldosteronism: a prospective single-center study.BMC Surg. 2024 Aug 24;24(1):242. doi: 10.1186/s12893-024-02530-z. BMC Surg. 2024. PMID: 39182043 Free PMC article.
-
Clinical value of sublingual microcirculatory dysfunction for screening for primary aldosteronism in hypertensive patients.Front Endocrinol (Lausanne). 2025 Jul 17;16:1561503. doi: 10.3389/fendo.2025.1561503. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40747303 Free PMC article.
-
Clinical Characteristics of Target Organ Damage in Primary Aldosteronism with or without Metabolic Syndrome.J Diabetes Res. 2022 Sep 7;2022:8932133. doi: 10.1155/2022/8932133. eCollection 2022. J Diabetes Res. 2022. PMID: 36117521 Free PMC article.
-
68Ga-Pentixafor PET/CT for the assessment of therapeutic outcomes following superselective adrenal arterial embolization in patients with primary aldosteronism.EJNMMI Res. 2025 Jan 16;15(1):5. doi: 10.1186/s13550-024-01194-3. EJNMMI Res. 2025. PMID: 39821475 Free PMC article.
References
-
- Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889‐1916. - PubMed
-
- Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126‐148. - PubMed
-
- Rossi GP. Primary aldosteronism: JACC State‐of‐the‐Art Review. J Am Coll Cardiol. 2019;74(22):2799‐2811. - PubMed
-
- Mulatero P, Monticone S, Bertello C, et al. Long‐term cardio‐ and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98(12):4826‐4833. - PubMed
-
- Monticone S, D'Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta‐analysis. Lancet Diabetes Endocrinol. 2018;6(1):41‐50. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials